DELFI Diagnostics

DELFI Diagnostics is a private, pre-revenue diagnostics company pioneering a novel approach to early cancer detection through fragmentomics—the analysis of cfDNA fragmentation patterns. Its core technology uses machine learning to scan millions of data points from a simple blood draw, aiming to detect cancer signals without relying solely on known mutations. The company is led by an experienced team with backgrounds from Illumina, GRAIL, and major academic institutions and is currently advancing its first product, FirstLook Lung, through clinical validation.

Fragmentomics platform analyzing cell-free DNA (cfDNA) fragmentation patterns using low-coverage whole-genome sequencing and machine learning for early cancer detection.

DELFI competes in the crowded liquid biopsy for early detection space, facing well-capitalized rivals like GRAIL (Galleri MCED test), Guardant Health (Shield), Exact Sciences, and Freenome. Its differentiation lies in its fragmentomics approach, which does not rely on detecting known mutations or methylation, but this unproven paradigm must demonstrate superior or comparable performance to gain market share.